Literature DB >> 3674403

Coupled-enzyme and direct assays for uroporphyrinogen III synthase activity in human erythrocytes and cultured lymphoblasts. Enzymatic diagnosis of heterozygotes and homozygotes with congenital erythropoietic porphyria.

S F Tsai1, D F Bishop, R J Desnick.   

Abstract

Rapid and reproducible assays for uroporphyrinogen III synthase (URO-S; EC 4.2.1.75) have been developed and used to determine the enzymatic activity in human erythrocytes and cultured lymphoid cells. In the coupled-enzyme assay, porphobilinogen was first converted to hydroxymethylbilane, the natural substrate for URO-S, by hydroxymethylbilane synthase which was conveniently obtained from heat-treated erythrocyte lysates. In the direct assay, synthetic hydroxymethylbilane was used as substrate. In both assays, the uroporphyrinogen reaction products were oxidized to their respective uroporphyrin isomers, which were then resolved and quantitated by reversed-phase high-pressure liquid chromatography. Both assays were optimized for pH, substrate concentration, and linearity with time and protein concentration. The mean URO-S activities in normal human erythrocyte lysates determined by the coupled-enzyme and direct assays were 7.41 +/- 1.35 and 7.64 +/- 1.73 units/mg protein, respectively. In normal human cultured lymphoid cells, the mean activities were 13.7 +/- 1.39 and 17.6 +/- 1.15 units/mg protein for the coupled-enzyme and direct assays, respectively. In four families with congenital erythropoietic porphyria, both assays reliably identified the markedly decreased URO-S activities in erythrocytes and cultured lymphoid cells from affected homozygotes and the half-normal activities in these sources from obligate heterozygotes. The coupled-enzyme assay was easier to perform and was suited for clinical diagnostic assays and for monitoring enzyme purification procedures, while the direct assay, which required substrate preparation and technical dexterity, was best for kinetic studies of URO-S.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3674403     DOI: 10.1016/0003-2697(87)90554-9

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  12 in total

1.  Regional assignment of the human uroporphyrinogen III synthase (UROS) gene to chromosome 10q25.2----q26.3.

Authors:  K H Astrin; C A Warner; H W Yoo; P J Goodfellow; S F Tsai; R J Desnick
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

2.  Feline congenital erythropoietic porphyria: two homozygous UROS missense mutations cause the enzyme deficiency and porphyrin accumulation.

Authors:  Sonia Clavero; David F Bishop; Urs Giger; Mark E Haskins; Robert J Desnick
Journal:  Mol Med       Date:  2010-05-12       Impact factor: 6.354

3.  Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R.

Authors:  Arola Fortian; Esperanza González; David Castaño; Juan M Falcon-Perez; Oscar Millet
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

4.  Congenital erythropoietic porphyria: characterization of murine models of the severe common (C73R/C73R) and later-onset genotypes.

Authors:  David F Bishop; Sonia Clavero; Narla Mohandas; Robert J Desnick
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

5.  Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions.

Authors:  David F Bishop; Annika Johansson; Robert Phelps; Amr A Shady; Maria C M Ramirez; Makiko Yasuda; Andres Caro; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-02-09       Impact factor: 11.025

6.  Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.

Authors:  Sonia Clavero; David F Bishop; Mark E Haskins; Urs Giger; Raili Kauppinen; Robert J Desnick
Journal:  Hum Mol Genet       Date:  2009-11-24       Impact factor: 6.150

7.  Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells.

Authors:  F Géronimi; E Richard; I Lamrissi-Garcia; M Lalanne; C Ged; I Redonnet-Vernhet; F Moreau-Gaudry; H de Verneuil
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

8.  Human uroporphyrinogen III synthase: molecular cloning, nucleotide sequence, and expression of a full-length cDNA.

Authors:  S F Tsai; D F Bishop; R J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene.

Authors:  C A Warner; H W Yoo; A G Roberts; R J Desnick
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

10.  Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.

Authors:  Aurélie Bedel; Miguel Taillepierre; Véronique Guyonnet-Duperat; Eric Lippert; Pierre Dubus; Sandrine Dabernat; Thibaud Mautuit; Bruno Cardinaud; Catherine Pain; Benoît Rousseau; Magalie Lalanne; Cécile Ged; Yann Duchartre; Emmanuel Richard; Hubert de Verneuil; François Moreau-Gaudry
Journal:  Am J Hum Genet       Date:  2012-07-13       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.